3d
Zacks Investment Research on MSNAligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue EstimatesAligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago. These ...
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses ...
is labelled in the EU to treat cholestatic pruritus – itching caused by impaired bile formation or flow – in children aged six months and over with ALGS, a disease caused by a genetic mutation ...
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results